{
    "id": 27328,
    "fullName": "SDC4 - NRG1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SDC4-NRG1 results from the fusion of SDC4 and NRG1 (PMID: 28950338). SDC4-NRG1 has been identified in lung adenocarcinoma and squamous cell carcinoma (PMID: 29610121, PMID: 28950338, PMID: 25531467), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 1975,
                    "pubMedId": 25531467,
                    "title": "Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25531467"
                },
                {
                    "id": 11263,
                    "pubMedId": 29610121,
                    "title": "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610121"
                },
                {
                    "id": 10433,
                    "pubMedId": 28950338,
                    "title": "Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28950338"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6385,
        "geneSymbol": "SDC4",
        "terms": [
            "SDC4",
            "SYND4"
        ]
    },
    "variant": "SDC4 - NRG1",
    "createDate": "12/14/2017",
    "updateDate": "01/23/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3084,
                "geneSymbol": "NRG1",
                "terms": [
                    "NRG1",
                    "ARIA",
                    "GGF",
                    "GGF2",
                    "HGL",
                    "HRG",
                    "HRG1",
                    "HRGA",
                    "MST131",
                    "MSTP131",
                    "NDF",
                    "NRG1-IT2",
                    "SMDF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 13747,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung cancer patient harboring SDC4-NRG1 did not respond to treatment with Gilotrif (afatinib) (PMID: 29610121; NCT01966445).",
            "molecularProfile": {
                "id": 28756,
                "profileName": "SDC4 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11263,
                    "pubMedId": 29610121,
                    "title": "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610121"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12565,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring SDC4-NRG1 demonstrated a lasting response when treated with Gilotrif (afatinib) (PMID: 28950338).",
            "molecularProfile": {
                "id": 28756,
                "profileName": "SDC4 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10433,
                    "pubMedId": 28950338,
                    "title": "Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28950338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28756,
            "profileName": "SDC4 - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}